Obigen Pharma Inc. (TPEX:7876)

Market Cap	4.09B
Revenue (ttm)	n/a
Net Income	-325.96M
EPS	-3.07
Shares Out	106.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	106,070
Average Volume	241,737
Open	38.70
Previous Close	38.55
Day's Range	37.80 - 38.70
52-Week Range	34.55 - 69.00
Beta	n/a
RSI	49.49
Earnings Date	n/a

About Obigen Pharma

Obigen Pharma Inc. engages in research, manufacturing, and promotion of biotechnology and novel botulinum toxin. Preparations in Taiwan. Its lead product OBI-858, a 760 kDa novel toxin protein which fermented and purified from clostridium botulinum type A bacteria, which is in Phase II clinical trial. The company was founded in 2020 and is based in Zhubei, Taiwan.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2020
• Employees: 60
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7876